Retrobulbar optic neuritis after pamidronate administration in a patient with a history of cutaneous porphyria

Clinical Rheumatology

Volumn 16, Issue 1, 1997, Pages 93-95

  Des Grottes, J M ^b   Schrooyen, M ^a   Dumon, J C ^b   Body, J J ^a,b  

^a JULES BORDET INSTITUTE   (Belgium)

^b SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

bisphosphonates; optic neuritis; osteoporosis; pamidronate; porphyria

Indexed keywords

CALCIUM; CHLOROQUINE; DICLOFENAC; ETIDRONIC ACID; PAMIDRONIC ACID; PREDNISOLONE; VITAMIN D;

ADULT; ARTICLE; CASE REPORT; FEMALE; HUMAN; OSTEOPOROSIS; PORPHYRIA; PRIORITY JOURNAL; RETROBULBAR OPTIC NEUROPATHY;

EID: 0031048323     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02238770     Document Type: Article

References (15)

1. Body JJ. Bone metastases and tumor-induced hypercalcemia. Current Opinion in Oncology 1992;4:624-31.
2. Fleisch H. New bisphosphonates in osteoporosis. Osteopoiosis Int 1993;2:S15-22.
3. Thiébaud D, Burckhardt P, Melchior J, Eckert P, Jacquet AF, Schnyder P, Gobelet C. Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporosis Int 1994;4:76-83.
4. Stettler E.R. Central epidemiology and drug safety. Ciba, Basle, Switzerland: personal communication.
5. Desnick RJ, Anderson KE. Heme biosynthesis and its disorders: the porphyrias and sideroblastic anemias. In: Hematology: Basic principles and practice. Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Cohen HJ, eds. Churchill Livingstone, New York 1991, Chap. 30, 352-357
6. Sevel D, Burger D. Ocular involvement in cutaneous porphyria. Arch Ophtal 1971;85:580-5.
7. Wood AJ. Adverse reactions to drugs. In Harrison's principles of internal medicine, 13th edition Editors, K.J. Isselbacher et al., McGraw-Hill Inc 1994, Chap. 67, 405-12.
8. Body JJ, Dumon JC. Treatment of tumor-induced hypercalcaemia with the bisphosphonate pamidronate: Dose-response relationship and influence of the tumour type. Ann Oncol 1994;5: 359-63.
9. Fitton A, Mc. Tavish D. Pamidronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1991;41:289-318.
10. Macarol V, Fraundfelder FT. Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 1994;118:220-24.
11. Siris ES. Bisphosphonates and iritis. Lancet 1993;341:436-37.
12. Wakefield D, Lloyd A. The role of cytokines in the pathogenesis of inflammatory eye disease. Cytokine 1992;4:1-5.
13. Schweitzer DH, Oostendorp-Van de Ruit M, Van der Pluijm G, Löwik CWGM, Papapoulos SE. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 1995;10:956-62.
14. Sauty A, Pechertorfer M, Fioroni P, Juillerat L, Leuenberger Ph, Burckhardt P, Thiébaud D. Serum levels of TNF a and IL-6 in patients treated by Pamidronate, Clodronate and BM 21.0955. Bone Miner 1994;25 (Suppl.1):S69.
15. Oliveri MB, Mautalen C, Mega M, Rossi E. Congenital erythropoietic porphyria - Skeletal manifestations and effects of pamidronate treatment. Bone 1994;15:101-4.